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Canonical Notch signaling is initiated by γ-secretase-mediated cleavage of the Notch recep-
tor, leading to the release of the active intra-cellular domain of Notch that migrates to
the nucleus and interacts with RBP-Jκ, resulting in the activation of downstream target
genes. While canonical Notch signaling is well known to play an active role in several
steps during development as well in multiple cell fate decisions, recent evidence from both
invertebrate and vertebrate systems indicates that non-canonical, RBP-Jκ-independent sig-
naling is important in several cellular processes including oncogenesis and activation of T
lymphocytes. These observations raise the possibility that, through an understanding of
non-canonical Notch signaling, novel strategies for inhibiting Notch signaling may prove
useful in the design of therapies targeted to block aberrant Notch activity. In this mini-
review, we will examine the current data demonstrating a non-canonical role for Notch
signaling in both cancer and the immune system and suggest a better understanding of
non-canonical signaling may reveal novel strategies to block Notch signaling in disease.
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INTRODUCTION
Notch is a trans-membrane protein with four family members
(Notch 1–4). Canonical Notch signaling is initiated by interac-
tion of the Notch protein with a cell bound ligand (Delta-like
1, 3, 4 or Jagged 1, 2) and results in cleavage of Notch, initially
by ADAM10 and ADAM17 proteases, followed by cleavage by the
gamma-secretase complex (1–3). At the completion of this process,
the Notch intra-cellular domain (NICD) translocates into the
nucleus and interacts with RBPJκ/CSL, a transcriptional repres-
sor. Upon interaction with NICD, RBPJκ/CSL is converted into a
potent transcriptional activator of downstream target genes (4).
However, more recent studies reveal the existence of several
other modes of Notch signaling generally referred to as non-
canonical Notch signaling (5). Interestingly, many instances of
non-canonical signaling are associated with potentially patholog-
ical conditions including cancer and activation of the immune
system while many normal cellular processes require canonical
Notch signaling. For example, it is likely that early development
in the mammalian embryo requires canonical Notch signaling
since deletion of RBP-Jκ mimics’ deletion of Notch1 (6, 7). Several
other physiological processes, such as maintenance of the intestinal
epithelium, also require canonical Notch signaling (8). There-
fore, it is possible that blockade of non-canonical Notch signaling
may provide opportunities to inhibit some instances of patho-
logical Notch signaling leaving many other normal physiological
processes intact. However, since non-canonical Notch signaling
is not as well characterized as the canonical signaling pathway,
more in-depth inquiries in this area are likely to reveal potential
new targets to manipulate non-canonical Notch signaling. Below,
we describe a number of instances where non-canonical Notch
signaling is associated with cancer or abnormal immune function
and we propose that a better understanding of these pathways may
uncover new opportunities for therapeutic approaches.
NON-CANONICAL NOTCH SIGNALING IN CANCER
The first indication for a role of Notch pathway in oncogenesis
came from Aster et al. (9) and Pear et al. (10) in T-cell acute lym-
phoblastic leukemia (T-ALL) in which chromosomal translocation
of the Notch1 gene was identified as a cause of T-cell oncogene-
sis. In later reports, the Notch pathway has been associated with
tumorigenesis and cancer progression in the other cancers includ-
ing breast, ovarian, cervical, lung, prostate carcinomas, gliomas,
and mesotheliomas (6, 9–16). It is well documented that Notch
signaling regulates proliferation, differentiation, and survival of
tumor cells (17, 18) and also is reported to maintain the stem
cell-like characteristics of cancer stem cells (19–21). Notch is also
required for further progression of differentiated cancer cells by
regulating metabolism, survival, and transcription in these cells.
In addition to its role in tumorigenesis, Notch has also been
reported to act as a tumor suppressor in certain cell types such
as skin epithelium (22). This observation makes it quite clear
that an understanding of individual Notch signaling pathways is
important for the rational therapeutic manipulation of Notch.
Inhibition of γ-secretase does not block all Notch-related func-
tions in tumor cells, suggesting a role for non-canonical Notch
signaling in transformed cells (6, 8, 9, 11–13, 16). Addition-
ally, transformation of baby rat kidney cells through coopera-
tion between the adenoviral E1A protein and NICD does not
require the RBPJκ/CSL binding domain of NICD, suggesting that
transformation in this system may be non-canonical. However,
non-canonical nuclear localization of NICD was still required for
oncogenesis (23, 24).
NON-CANONICAL NOTCH SIGNALING IN LEUKEMIA
Studies by Vacca et al. (25) suggest that non-canonical Notch3
signaling regulates T-cell development and leukemia through acti-
vation of the NF-κB pathway. In their transgenic mouse model,
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Notch3 overexpression, specifically in T cells, led to the devel-
opment of leukemia (25). This group showed that increased
Notch3 expression enabled constitutive activation of NF-κB and
demonstrated that Notch3 interacts with IKKα to maintain NF-κB
activity (25).
In human myelogenous leukemia cells, Notch1 directly inter-
acts with the transcription factor, YY1, to drive expression of
the oncogenic transcription factor c-myc independently of CSL
(26). In HPV-driven human cervical cancer, non-canonical Notch
signaling enables oncogenesis, independently of CSL, via PI3K
pathway (27). However, little is known about how non-canonical
Notch signaling drives transformation in these situations.
NON-CANONICAL NOTCH SIGNALING IN THE MAMMARY GLAND
Raafat et al. (28), using conditional RBPJκ knockout mice, revealed
that non-canonical Notch4 signaling is involved in mammary
gland tumorigenesis, whereas canonical Notch4 was required
for the development of mammary glands (28). This differential
regulation provides an attractive opportunity for targeting non-
canonical Notch signaling to dampen oncogenesis while enabling
intact tissue homeostasis and development to occur via canonical
Notch signaling. Another study suggests an RBPJκ-independent
role for Notch4 signaling in the survival of endothelial cell lines
(29). Furthermore, during breast cancer progression, Notch sig-
naling plays a role in epithelial transformation independent of
CSL (30). These studies further emphasize the importance of
non-canonical Notch signaling in breast cancer cell survival and
progression.
Additionally, in breast cancer cell lines, non-canonical Notch
signaling is known to regulate IL-6 expression, and IL-6, in turn,
acts on tumor cells to further increase their oncogenic potential.
In this study, cytoplasmic NICD interaction with the NF-κB path-
way induced IL-6 expression (31). These studies, in addition to
those reported above in leukemic T cells (25), support a role for
non-canonical Notch signaling via NF-κB pathway in oncogenesis.
NON-CANONICAL NOTCH SIGNALING IN APOPTOSIS AND
METABOLISM
Non-canonical Notch signaling also is implicated in the regulation
of metabolism in tumor cells. Recent studies from Perumalsamy
et al. (32) demonstrated that non-nuclear, either cytoplasmic or
membrane tethered, NICD blocks starvation-induced apoptosis
in HeLa, a cervical cancer cell line. This group also showed that
nuclear retention of NICD abrogates its anti-apoptotic activity
thus demonstrating that, in their system, Notch controls apop-
tosis via a non-canonical, cytosolic pathway. Their data further
suggest that non-canonical Notch regulation of apoptosis occurs
through the mTOR–Rictor pathway (32). Another study linking
Notch to metabolism examined the role of Notch in regulating
neuronal stem cells (33). This report demonstrated an interac-
tion between Notch and the PTEN-induced kinase 1 (PINK1)
and provides evidence that the Notch/PINK1 interaction influ-
ences mitochondrial function and activates the mTORC2/Akt
pathway. This non-canonical Notch signaling induced prolifer-
ation and tumor stem cell maintenance through mitochondrial
and metabolic pathways. Additionally, in this study, the authors
observed localization of full length Notch1 on the mitochondrial
membrane further linking at least some forms of non-canonical
Notch signaling to the mitochondria (33).
Non-canonical Notch signaling is known to regulate hypoxic
pathways in transformed human cell lines (34). In this study, it
was shown that NICD sequesters a negative regulator of HIF-
1α resulting in increased protein levels of HIF-1α and, in turn,
increasing its downstream effects (34). Since hypoxia and meta-
bolic changes are hallmarks of tumor tissue, the emerging role of
non-canonical signaling in these pathways implies that there will
be increased recognition of non-canonical Notch signaling mech-
anisms and cross-talk with other important pathways in a variety
of tumor settings (35).
NON-CANONICAL NOTCH SIGNALING IN THE IMMUNE
SYSTEM
Notch signaling regulates some lineage decisions of hematopoietic
cells (36, 37), and enables generation of T cells at the expense of B
and myeloid cells in the early stages of hematopoietic cell develop-
ment. At later time points, Notch plays a key role in the survival,
proliferation, and differentiation of T cells. Notch signaling also
regulates the development of some innate lymphoid cells, marginal
zone B cells from precursor B cells, megakaryocytes, and cytotoxic
(CD8+) T-cell lymphocytes (CTLs) (38–43). Thus, as discussed
more extensively below, non-canonical Notch signaling is involved
in the development and function of several types of immune cells.
NON-CANONICAL NOTCH SIGNALING IN T-CELL ACTIVATION AND
DIFFERENTIATION
Notch is important in driving the differentiation of naïve CD4+ T
cells into specific T helper (Th) subsets and targeting Notch signal-
ing in Th cells provides the opportunity for immune modulation.
Studies in our lab demonstrate that GSI treatment significantly
reduces Th1, Th17, and induced Treg (iTreg) polarization (44,
45). Studies by other labs using different methods to block Notch
signaling showed that Th2 polarization is also driven by Notch sig-
naling (46, 47). We demonstrated a significant decrease in Th1 and
iTreg differentiation in conditional Notch1 knockout Th cells and
through the use of conditional RBPJκ knockout T cells, revealed
that Notch regulates Th cell differentiation into different Th cell
fates independent of RBPJκ and hence is non-canonical. Further-
more, our data showed that both activation and proliferation of
CD4+ T cells are not impaired by conditional deletion of RBPJκ
(45). Thus, CD4+ T-cell activation, proliferation, and differentia-
tion all require non-canonical Notch signaling, and recent data
from our lab suggest Notch, in conjunction with NF-κB, and
regulate this non-canonical signaling in CD4+ T cells. (45).
The possibility that non-canonical Notch signaling may occur
through activation of NF-κB is not surprising since links between
Notch and NF-κB have been documented by several groups includ-
ing our own (48, 49). In cells of the immune system, Notch3
in collaboration with NF-κB is reported to cooperatively reg-
ulate FoxP3 expression (50). Additionally, we recently reported
that Notch1 can initiate NF-κB activation via cytosolic interac-
tions with components of the T-cell signalosome. In particular,
cytosolic Notch1 drives the formation of the CARMA1, BCL10,
and MALT1 (CBM) complex that is essential for NF-κB activation
in T cells. These data demonstrated that cytosolic, rather than
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FIGURE 1 | Non-canonical Notch signaling pathways. Non-canonical Notch
signaling may occur either dependent or independent of ligand interaction.
Additionally, non-canonical Notch signaling may be γ-secretase dependent or
independent with the latter exerting its function as membrane bound Notch.
Non-canonical Notch signaling is independent of CSL/RBPJκ and, instead,
interacts with PI3K, mTORC2, AKT,Wnt, NFκB,YY1, or HIF-1α pathways at
either the cytoplasmic and/or nuclear levels. Non-canonical Notch signaling
regulates cell survival, metabolism, and differentiation through interaction
with these pathways in many important biological processes including
immunity and cancer.
nuclear, Notch1 drives CBM complex formation emphasizing the
non-canonical role of Notch1 in this process (49).
NON-CANONICAL NOTCH SIGNALING IN T-CELL METABOLISM
In addition to Notch signaling through NF-κB, non-canonical
Notch signaling is implicated in T-cell metabolism and cell sur-
vival. Upon lymphocyte activation, there is an immense change
in the metabolic activity of T cells to enable the production of
building blocks for cell division and growth as well as ATP produc-
tion. This metabolic switch is closely linked with cell survival. As
described above, Perumalsamy et al. (32) described a link between
non-canonical Notch signaling and the mTORC2-Akt cascade
(32). In this report, they also provide evidence that cell survival
of activated T cells is regulated by the interaction of cytoplas-
mic or membrane tethered NICD with the mTORC2-Akt cascade
and this may also be involved in cell metabolism (32). The same
group had previously demonstrated that interaction of Notch1 and
kinases involved in early T-cell activation (PI3K and p56lck) reg-
ulates an anti-apoptotic program in T cells through Akt signaling
(51). Interestingly, another group has demonstrated mitochondr-
ial localization of full length Notch1 protein in neuronal cells pro-
viding additional evidence in another system for non-canonical
Notch signaling in metabolism and cell survival (33).
A ROLE FOR LIGAND-INDEPENDENT ACTIVATION OF NOTCH
As described above, canonical Notch signaling begins with the
interaction between Notch and its ligand and this interaction
catalyzes a series of events leading to cleavage and release of NICD.
A conundrum in the immune system is the observation by our
group and others, that activation of the T-cell receptor leads to
rapid release of NICD (52, 53) and this may occur in the absence
of ligand. While the mechanism of Notch activation through the
TCR is poorly understood, a possible hint to this process is sug-
gested by studies ofDrosophila immune cells showing NICD can be
generated independently of ligand interaction and this is depen-
dent upon HIF-1α-mediated stabilization of NICD (52). Since
ligand-independent Notch activation can occur through HIF-1α
inDrosophila immune cells, it is tempting to speculate that this also
may occur in mammals (54). The observed ligand-independent
activation in immune cells of Drosophila may possibly be phys-
iologically relevant in mammals. There is no evidence that Th
cells express Notch ligands in the circulation while trafficking to
effector sites after initial priming in lymph nodes and continuous
Notch signaling could provide survival and differentiation signals
in the circulation; however, this remains speculative.
A role for membrane tethered Notch is found in dendritic cells,
a cell found at the nexus of the innate and adaptive immune system.
According to one recent study, in dendritic cells, membrane bound
Notch activates PI3 kinase. This non-canonical Notch signaling
regulates the production of the immune suppressive cytokine,
IL10, by dendritic cells in response to LPS (55).
Notch signaling in the immune system, while required for
normal immune function, also is linked to several diseases of
the immune system (38–41, 56–60). Aberrant Notch signaling is
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implicated in several autoimmune diseases including bone marrow
failure, experimental autoimmune encephalomyelitis, rheumatoid
arthritis, and type 1 diabetes (59,61–63). Many of these diseases are
caused, at least in part, by auto-reactive T cells. Since we know that
Th1 and Th17 cell differentiation requires non-canonical Notch
signaling, it is reasonable to envision a therapeutic strategy that
would block non-canonical Notch signaling perhaps leaving intact
other Notch signaling pathways important for normal function of
other cells and tissues. However, to achieve such a goal, it is essential
that we better understand the various pathways of non-canonical
Notch signaling.
SUMMARY AND FUTURE PERSPECTIVES
Notch signaling plays an important role in the fine tuning of
oncogenesis and immunity as well as many other essential bio-
logical processes. Here, we provide evidence for three types of
non-canonical Notch signaling: (i) γ-secretase regulated activa-
tion of the Notch pathway that occurs independently of ligand
interaction; (ii) NICD activity independent of RBPJκ/CSL; (iii)
membrane bound Notch signaling in the absence of cleavage by
the γ-secretase complex and, in some cases, independent of ligand
interaction (Figure 1).
The studies described in this review emphasize the role of
non-canonical Notch signaling in both cancer and the immune
system. These studies highlight the various strategies employed by
non-canonical Notch to drive a multitude of biological effects. A
clear appreciation of both canonical and non-canonical Notch
will deepen our understanding of the basic biology of Notch
signaling. Inhibitors are available for many of the signaling path-
ways involved in non-canonical Notch signaling (NF-κB, PI3K,
AKT, mTOR, HIF-1α, and β-catenin) and, in several instances,
these inhibitors have passed through clinical trials. Therefore, it
is possible to consider combination therapies where one of these
inhibitors,perhaps in conjunction with reduced doses of a gamma-
secretase inhibitor, might prove efficacious. For example, in T
cell-mediated autoimmunity, where we know Notch and NF-kB
cooperate to mediate aberrant Th1 activation (64), one might use
a combination of gamma-secretase inhibition with curcumin, a
neutracuetical known to inhibit NF-kB signaling (65). Thus, in
the near future, it will be possible to test the possibility that com-
bination therapy, using Notch inhibitors together with inhibitors
of these other pathways, may be more efficacious in the treat-
ment of diseases regulated by Notch. Careful delineation of Notch
signaling pathways both in normal cells and tissues as well as in
auto-reactive or oncogenic situations may produce a deeper and
more nuanced understanding of this important signaling pathway
and hence provide a roadmap for the identification of new and
novel drug targets useful in the treatment of disease.
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